Session 9－Smart Hospital & Homecare
Date: 26 July (Friday) 9:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
APAC Regulatory Policy Lead
Finny Liu is the APAC Regional Regulatory Policy Lead, Product Development Regulatory, at Roche based in Singapore.
Previously, she was the Head of APAC International Operations at Roche located in Singapore responsible for Asia Pacific regional management of life-cycle submissions for Roche products to ensure right first-time submissions to Health Authorities during Aug. 2013 to Jun. 2016.
Before joined Roche Taiwan in 2009 as Regulatory Affairs Director, she worked with several multinational companies, Novo Nordisk, AstraZeneca and Abbott and held positions of increasing responsibility including Clinical Research, Medical Information, Quality Assurance and Regulatory Affairs for pharmaceutical products, medical devices, and medical/ infant nutritional products.
Finny holds a Master Degree in Pharmaceutical Technology and a Bachelor Degree in Pharmacy, both from the National Taiwan University, Medical College. Session Speech Title & Synopsis: Personalized Healthcare – Roche’s Perspective
The dream of bringing about transformation in healthcare has been around for several years, but it wasn’t achievable because the digitization of healthcare has never been at the requisite level, until recently.
We are on the cusp of a transformation in healthcare. Our ability to understand and interpret unprecedented volumes of data allows a higher resolution view of each individual patient and puts the promise of truly Personalised Healthcare within reach. Personalised Healthcare (PHC) is transforming all aspects of our work, our industry, and healthcare as a whole.
We know that the use of real-world evidence, molecular information generated from next-generation sequencing, data from wearable devices and mobile apps and results of novel clinical trials can help transform the future of care. However, we need to combine and aggregate this information in a manner that enables answers to questions which meet the needs of patients. And for us to get to those meaningful answers, we need to have a certain breadth and depth and quality of that data.
It’s an exciting time for everyone working to improve outcomes in cancer and other diseases, and especially for the patients who will ultimately benefit from the modernization and individualization of healthcare. It's a privilege to be part of this evolution, but it’s also a responsibility. The patients are waiting, and we look forward to seeing what’s next.